Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 15, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory

Interventions

DRUG

Venetoclax

Venetoclax and 6-mercaptopurine

DRUG

6-mercaptopurine

Venetoclax and 6-mercaptopurine

Trial Locations (2)

RECRUITING

University Hospital Antwerp, Edegem

NOT_YET_RECRUITING

AZ Delta, Roeselare

All Listed Sponsors

lead

University Hospital, Antwerp

OTHER